The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model

Table 1 Correlations between miR-542-5p expression and the clinicopathological features of NSCLC

Parameters	n	The expression of miR-542-5p (2^-△Cq)	t	p
Tissue
NSCLC	125	1.952 ± 1.507	−11.703	< 0.001*
Adjacent lung	125	4.568 ± 1.993	−11.703	< 0.001*
Age (years)
< 60	57	1.945 ± 1.382	−0.052	0.958
≥ 60	68	1.959 ± 1.615	−0.052	0.958
Gender
Male	75	1.983 ± 1.475	0.279	0.783
Female	50	1.906 ± 1.568	0.279	0.783
Tumor size (cm)
< 3	60	1.979 ± 1.520	0.183	0.504
≥ 3	65	1.928 ± 1.506	0.183	0.504
Smoking history^a
Positive	30	2.622 ± 1.510	−1.004	0.319
Negative	38	2.266 ± 1.407	−1.004	0.319
TNM stage
I-II	54	2.822 ± 1.536	6.488	< 0.001*
III-IV	71	1.292 ± 1.101	6.488	< 0.001*
Lymph node metastasis
Positive	69	1.504 ± 1.266	3.905	< 0.001*
Negative	56	2.506 ± 1.604	3.905	< 0.001*
Vascular invasion
Positive	35	1.475 ± 1.305	2.247	0.026*
Negative	90	2.138 ± 1.545	2.247	0.026*
EGFR protein^b
low	17	0.739 ± 0.407	7.753	< 0.001*
high	40	3.049 ± 1.194	7.753	< 0.001*

ISSN: 1471-2407